MIRNA-503-5P inhibitor

MIRNA-503-5P inhibitor has been studied in 1 paper since 2022: none in people yet, 1 in animals. The research so far is in animals. The newest paper, May 13, 2022: “MicroRNA Expression Profiling in Age-Dependent Renal Impairment”.

Intervention

1 paper studies it3 findingsUpdated

See all 1 papers on MIRNA-503-5P inhibitor

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

None of its findings points the other way.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • Funder: Japan Society for the Promotion of Science
  • Animals1

What did studies of MIRNA-503-5P inhibitor find?

3

Studies of MIRNA-503-5P inhibitor measured 3 outcomes: age-dependent renal impairment, glomerulosclerosis and renal fibrosis.

Age-dependent renal impairment

no changein mice1

1 study
  1. MIRNA-503-5P inhibitor showed no clear effect on age-dependent renal impairment in SAMP1 mice.

    Animalsin SAMP1 micePEI-NPs5 nmol

More on Age-dependent renal impairment

Glomerulosclerosis

downin mice1

1 study
  1. MIRNA-503-5P inhibitor decreases glomerulosclerosis in mice (administered with PEI-NPs in SAMP1 mice).

    Animalsadministered with PEI-NPs in SAMP1 micePEI-NPskidney5 nmol

More on Glomerulosclerosis

Renal fibrosis

downin mice1

1 study
  1. MIRNA-503-5P inhibitor decreases renal fibrosis in mice (administered with PEI-NPs in SAMP1 mice).

    Animalsadministered with PEI-NPs in SAMP1 micePEI-NPskidney5 nmol

Latest